Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $69.50, for a total value of $208,500.00. Following the completion of the sale, the insider now directly owns 191,583 shares of the company’s stock, valued at approximately $13,315,018.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Clovis Oncology, Inc. (NASDAQ CLVS) opened at 76.01 on Wednesday. The stock’s market cap is $3.72 billion. The company’s 50-day moving average price is $73.35 and its 200-day moving average price is $69.15. Clovis Oncology, Inc. has a 52-week low of $25.50 and a 52-week high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The firm had revenue of $14.62 million during the quarter, compared to analyst estimates of $13.07 million. During the same period last year, the company posted ($2.07) earnings per share. The firm’s revenue was down 32.5% compared to the same quarter last year. Analysts expect that Clovis Oncology, Inc. will post ($7.56) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Gillian C. Ivers-Read Sells 3,000 Shares of Clovis Oncology, Inc. (CLVS) Stock” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/20/gillian-c-ivers-read-sells-3000-shares-of-clovis-oncology-inc-clvs-stock.html.
Several hedge funds and other institutional investors have recently made changes to their positions in CLVS. Phocas Financial Corp. purchased a new stake in shares of Clovis Oncology during the second quarter valued at $112,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Clovis Oncology by 71.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 758 shares during the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Clovis Oncology by 160.7% during the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Clovis Oncology by 3.7% during the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 100 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Clovis Oncology during the first quarter valued at $185,000. 99.03% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have commented on the company. Leerink Swann reissued a “buy” rating and issued a $107.00 target price on shares of Clovis Oncology in a report on Monday. Royal Bank Of Canada began coverage on Clovis Oncology in a research note on Thursday, September 14th. They set a “sector perform” rating and a $81.00 price target for the company. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Monday, September 11th. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Monday, September 11th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 18th. Nine analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $84.91.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.